26 February 2021 (Friday) - ASH Update

The nice people at the ASH sent their update on myeloma today. Like much of their stuff this was (for the most part) rather too clinical for me… but background information is always useful. Especially when it is free…


Teclistamab Shows Promise for Myeloma in Phase I Trial
Approximately three-quarters of patients with relapsed and/or refractory myeloma responded to treatment with teclistamab, according to results presented at the 2020 ASH Annual Meeting.
Guest Commentary: The Future of Chronic Graft-Versus-Host Disease
Steven Pavletic, MD, and Kirk Schultz, MD, report on the progress and challenges in the management of chronic graft-versus-host disease – the subject of a recent National Institutes of Health Consensus Conference.
BOSTON: Selinexor Improves Progression-Free Survival in Relapsed/Refractory Myeloma
Results from the phase III BOSTON trial published in The Lancet supported the FDA’s approval of selinexor plus bortezomib and dexamethasone for the treatment of adults with multiple myeloma who have received at least one prior therapy

No comments:

Post a Comment